{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T20:48:43Z","timestamp":1793911723400,"version":"4.8.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T00:00:00Z","timestamp":1764720000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T00:00:00Z","timestamp":1768176000000},"content-version":"vor","delay-in-days":40,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-025-67087-8","type":"journal-article","created":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T09:52:13Z","timestamp":1764755533000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Letrozole, abemaciclib and metformin in endometrial cancer: a non-randomized phase 2 trial"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1032-1479","authenticated-orcid":false,"given":"Panagiotis A.","family":"Konstantinopoulos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ningxuan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard T.","family":"Penson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tien V.","family":"Le","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susana","family":"Campos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn","family":"Krasner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexi A.","family":"Wright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Porter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Horowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0315-2152","authenticated-orcid":false,"given":"Sara","family":"Bouberhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joyce F.","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Hindenach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Sawyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lani","family":"Koppermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Hayes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1331-3845","authenticated-orcid":false,"given":"Madeline","family":"Polak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5262-1245","authenticated-orcid":false,"given":"Meghan","family":"Shea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Page","family":"Widick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su-Chun","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1159-5658","authenticated-orcid":false,"given":"Cesar","family":"Castro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan H.","family":"Beumer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ursula A.","family":"Matulonis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7533-7853","authenticated-orcid":false,"given":"Elizabeth K.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,3]]},"reference":[{"key":"67087_CR1","doi-asserted-by":"publisher","first-page":"5511","DOI":"10.1200\/JCO.2024.42.16_suppl.5511","volume":"42","author":"A Green","year":"2024","unstructured":"Green, A. et al. A phase II study of fulvestrant and abemaciclib in hormone receptor positive advanced or recurrent endometrial cancer. J. Clin. Oncol. 42, 5511\u20135511 (2024).","journal-title":"J. Clin. Oncol."},{"key":"67087_CR2","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1200\/JCO.22.00628","volume":"41","author":"PA Konstantinopoulos","year":"2023","unstructured":"Konstantinopoulos, P. A. et al. A phase II, two-stage study of letrozole and abemaciclib in estrogen receptor-positive recurrent endometrial cancer. J. Clin. Oncol. 41, 599\u2013608 (2023).","journal-title":"J. Clin. Oncol."},{"key":"67087_CR3","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.ygyno.2024.12.003","volume":"192","author":"MR Mirza","year":"2025","unstructured":"Mirza, M. R. et al. Palbociclib plus letrozole in estrogen receptor-positive advanced\/recurrent endometrial cancer: Double-blind placebo-controlled randomized phase II ENGOT-EN3\/PALEO trial. Gynecol. Oncol. 192, 128\u2013136 (2025).","journal-title":"Gynecol. Oncol."},{"key":"67087_CR4","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.ygyno.2024.10.006","volume":"191","author":"K Yonemori","year":"2024","unstructured":"Yonemori, K. et al. Imlunestrant, an oral selective estrogen receptor degrader, as monotherapy and combined with abemaciclib, in recurrent\/advanced ER-positive endometrioid endometrial cancer: results from the phase 1a\/1b EMBER study. Gynecol. Oncol. 191, 172\u2013181 (2024).","journal-title":"Gynecol. Oncol."},{"key":"67087_CR5","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.celrep.2019.02.111","volume":"27","author":"E Toska","year":"2019","unstructured":"Toska, E. et al. PI3K inhibition activates SGK1 via a feedback loop to promote chromatin-based regulation of ER-dependent gene expression. Cell Rep. 27, 294\u2013306 e295 (2019).","journal-title":"Cell Rep."},{"key":"67087_CR6","doi-asserted-by":"publisher","first-page":"x3","DOI":"10.1093\/annonc\/mdz281","volume":"30","author":"N Vasan","year":"2019","unstructured":"Vasan, N., Toska, E. & Scaltriti, M. Overview of the relevance of PI3K pathway in HR-positive breast cancer. Ann. Oncol. 30, x3\u2013x11 (2019).","journal-title":"Ann. Oncol."},{"key":"67087_CR7","doi-asserted-by":"publisher","first-page":"8810","DOI":"10.18632\/oncotarget.24256","volume":"9","author":"W Yang","year":"2018","unstructured":"Yang, W. et al. Estrogen receptor alpha drives mTORC1 inhibitor-induced feedback activation of PI3K\/AKT in ER+ breast cancer. Oncotarget 9, 8810\u20138822 (2018).","journal-title":"Oncotarget"},{"key":"67087_CR8","doi-asserted-by":"publisher","first-page":"2301","DOI":"10.1158\/0008-5472.CAN-15-0728","volume":"76","author":"MT Herrera-Abreu","year":"2016","unstructured":"Herrera-Abreu, M. T. et al. Early adaptation and acquired resistance to CDK4\/6 inhibition in estrogen receptor-positive breast cancer. Cancer Res. 76, 2301\u20132313 (2016).","journal-title":"Cancer Res."},{"key":"67087_CR9","doi-asserted-by":"publisher","DOI":"10.1200\/PO-24-00882","volume":"9","author":"PA Konstantinopoulos","year":"2025","unstructured":"Konstantinopoulos, P. A. et al. Serial circulating tumor DNA sequencing to monitor response and define acquired resistance to letrozole\/abemaciclib in endometrial cancer. JCO Precis Oncol. 9, e2400882 (2025).","journal-title":"JCO Precis Oncol."},{"key":"67087_CR10","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.ccr.2014.05.020","volume":"26","author":"SR Vora","year":"2014","unstructured":"Vora, S. R. et al. CDK 4\/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors. Cancer Cell 26, 136\u2013149 (2014).","journal-title":"Cancer Cell"},{"key":"67087_CR11","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1056\/NEJMoa2404625","volume":"391","author":"NC Turner","year":"2024","unstructured":"Turner, N. C. et al. Inavolisib-based therapy in PIK3CA-mutated advanced breast cancer. N. Engl. J. Med. 391, 1584\u20131596 (2024).","journal-title":"N. Engl. J. Med."},{"key":"67087_CR12","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.4161\/cc.10.13.16244","volume":"10","author":"AS Green","year":"2011","unstructured":"Green, A. S. et al. LKB1\/AMPK\/mTOR signaling pathway in hematological malignancies: from metabolism to cancer cell biology. Cell Cycle 10, 2115\u20132120 (2011).","journal-title":"Cell Cycle"},{"key":"67087_CR13","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1111\/j.1753-0407.2011.00119.x","volume":"3","author":"D Li","year":"2011","unstructured":"Li, D. Metformin as an antitumor agent in cancer prevention and treatment. J. Diabetes 3, 320\u2013327 (2011).","journal-title":"J. Diabetes"},{"key":"67087_CR14","doi-asserted-by":"publisher","first-page":"2556","DOI":"10.1093\/annonc\/mdr037","volume":"22","author":"A Clements","year":"2011","unstructured":"Clements, A. et al. Metformin in prostate cancer: two for the price of one. Ann. Oncol. 22, 2556\u20132560 (2011).","journal-title":"Ann. Oncol."},{"key":"67087_CR15","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1172\/JCI13505","volume":"108","author":"G Zhou","year":"2001","unstructured":"Zhou, G. et al. Role of AMP-activated protein kinase in mechanism of metformin action. J. Clin. Invest. 108, 1167\u20131174 (2001).","journal-title":"J. Clin. Invest."},{"key":"67087_CR16","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s10549-010-0763-9","volume":"123","author":"M Zakikhani","year":"2010","unstructured":"Zakikhani, M., Blouin, M. J., Piura, E. & Pollak, M. N. Metformin and rapamycin have distinct effects on the AKT pathway and proliferation in breast cancer cells. Breast Cancer Res. Treat. 123, 271\u2013279 (2010).","journal-title":"Breast Cancer Res. Treat."},{"key":"67087_CR17","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1056\/NEJM199602293340906","volume":"334","author":"CJ Bailey","year":"1996","unstructured":"Bailey, C. J. & Turner, R. C. Metformin. N. Engl. J. Med. 334, 574\u2013579 (1996).","journal-title":"N. Engl. J. Med."},{"key":"67087_CR18","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1007\/978-3-642-38007-5_21","volume":"159","author":"A Leone","year":"2014","unstructured":"Leone, A., Di Gennaro, E., Bruzzese, F., Avallone, A. & Budillon, A. New perspective for an old antidiabetic drug: metformin as anticancer agent. Cancer Treat. Res. 159, 355\u2013376 (2014).","journal-title":"Cancer Treat. Res."},{"key":"67087_CR19","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1002\/cam4.353","volume":"4","author":"KM Schuler","year":"2015","unstructured":"Schuler, K. M. et al. Antiproliferative and metabolic effects of metformin in a preoperative window clinical trial for endometrial cancer. Cancer Med. 4, 161\u2013173 (2015).","journal-title":"Cancer Med."},{"key":"67087_CR20","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/j.ygyno.2016.10.011","volume":"143","author":"PT Soliman","year":"2016","unstructured":"Soliman, P. T. et al. Prospective evaluation of the molecular effects of metformin on the endometrium in women with newly diagnosed endometrial cancer: a window of opportunity study. Gynecol. Oncol. 143, 466\u2013471 (2016).","journal-title":"Gynecol. Oncol."},{"key":"67087_CR21","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1038\/s41392-020-0203-1","volume":"5","author":"Y Ma","year":"2020","unstructured":"Ma, Y. et al. A CRISPR knockout negative screen reveals synergy between CDKs inhibitor and metformin in the treatment of human cancer in vitro and in vivo. Signal Transduct. Target Ther. 5, 152 (2020).","journal-title":"Signal Transduct. Target Ther."},{"key":"67087_CR22","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.87062","volume":"1","author":"LM Sholl","year":"2016","unstructured":"Sholl, L. M. et al. Institutional implementation of clinical tumor profiling on an unselected cancer population. JCI Insight 1, e87062 (2016).","journal-title":"JCI Insight"},{"key":"67087_CR23","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1158\/2159-8290.CD-11-0184","volume":"2","author":"N Wagle","year":"2012","unstructured":"Wagle, N. et al. High-throughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencing. Cancer Discov. 2, 82\u201393 (2012).","journal-title":"Cancer Discov."},{"key":"67087_CR24","doi-asserted-by":"publisher","first-page":"751","DOI":"10.5858\/arpa.2016-0527-OA","volume":"141","author":"EP Garcia","year":"2017","unstructured":"Garcia, E. P. et al. Validation of oncopanel: a targeted next-generation sequencing assay for the detection of somatic variants in cancer. Arch. Pathol. Lab. Med. 141, 751\u2013758 (2017).","journal-title":"Arch. Pathol. Lab. Med."},{"key":"67087_CR25","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1200\/EDBK_281085","volume":"40","author":"ES Knudsen","year":"2020","unstructured":"Knudsen, E. S., Shapiro, G. I. & Keyomarsi, K. Selective CDK4\/6 inhibitors: biologic outcomes, determinants of sensitivity, mechanisms of resistance, combinatorial approaches, and pharmacodynamic biomarkers. Am. Soc. Clin. Oncol. Educ. Book 40, 115\u2013126 (2020).","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"67087_CR26","doi-asserted-by":"publisher","first-page":"81","DOI":"10.2165\/11534750-000000000-00000","volume":"50","author":"GG Graham","year":"2011","unstructured":"Graham, G. G. et al. Clinical pharmacokinetics of metformin. Clin. Pharmacokinet. 50, 81\u201398 (2011).","journal-title":"Clin. Pharmacokinet."},{"key":"67087_CR27","doi-asserted-by":"publisher","first-page":"3638","DOI":"10.1200\/JCO.2017.75.6155","volume":"35","author":"MP Goetz","year":"2017","unstructured":"Goetz, M. P. et al. MONARCH 3: abemaciclib as initial therapy for advanced breast cancer. J. Clin. Oncol. 35, 3638\u20133646 (2017).","journal-title":"J. Clin. Oncol."},{"key":"67087_CR28","doi-asserted-by":"publisher","first-page":"3987","DOI":"10.1200\/JCO.20.02514","volume":"38","author":"SRD Johnston","year":"2020","unstructured":"Johnston, S. R. D. et al. Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER2-, node-positive, high-risk, early breast cancer (monarchE). J. Clin. Oncol. 38, 3987\u20133998 (2020).","journal-title":"J. Clin. Oncol."},{"key":"67087_CR29","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1002\/cpt.1296","volume":"105","author":"JC Chappell","year":"2019","unstructured":"Chappell, J. C. et al. Abemaciclib inhibits renal tubular secretion without changing glomerular filtration rate. Clin. Pharm. Ther. 105, 1187\u20131195 (2019).","journal-title":"Clin. Pharm. Ther."},{"key":"67087_CR30","doi-asserted-by":"publisher","first-page":"e61537","DOI":"10.1371\/journal.pone.0061537","volume":"8","author":"R Sarfstein","year":"2013","unstructured":"Sarfstein, R. et al. Metformin downregulates the insulin\/IGF-I signaling pathway and inhibits different uterine serous carcinoma (USC) cells proliferation and migration in p53-dependent or -independent manners. PLoS One 8, e61537 (2013).","journal-title":"PLoS One"},{"key":"67087_CR31","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1080\/15384101.2016.1151582","volume":"15","author":"L Chen","year":"2016","unstructured":"Chen, L., Ahmad, N. & Liu, X. Combining p53 stabilizers with metformin induces synergistic apoptosis through regulation of energy metabolism in castration-resistant prostate cancer. Cell Cycle 15, 840\u2013849 (2016).","journal-title":"Cell Cycle"},{"key":"67087_CR32","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.1002\/mc.22696","volume":"56","author":"MA Abu El Maaty","year":"2017","unstructured":"Abu El Maaty, M. A., Strassburger, W., Qaiser, T., Dabiri, Y. & Wolfl, S. Differences in p53 status significantly influence the cellular response and cell survival to 1,25-dihydroxyvitamin D3-metformin cotreatment in colorectal cancer cells. Mol. Carcinog. 56, 2486\u20132498 (2017).","journal-title":"Mol. Carcinog."},{"key":"67087_CR33","doi-asserted-by":"publisher","first-page":"21914","DOI":"10.18632\/aging.203528","volume":"13","author":"TC Tortelli","year":"2021","unstructured":"Tortelli, T. C. et al. Metformin-induced chemosensitization to cisplatin depends on P53 status and is inhibited by Jarid1b overexpression in non-small cell lung cancer cells. Aging 13, 21914\u201321940 (2021).","journal-title":"Aging"},{"key":"67087_CR34","first-page":"2695","volume":"17","author":"SY Park","year":"2019","unstructured":"Park, S. Y., Kim, D. & Kee, S. H. Metformin-activated AMPK regulates beta-catenin to reduce cell proliferation in colon carcinoma RKO cells. Oncol. Lett. 17, 2695\u20132702 (2019).","journal-title":"Oncol. Lett."},{"key":"67087_CR35","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-021-01462-3","volume":"23","author":"JO Brett","year":"2021","unstructured":"Brett, J. O., Spring, L. M., Bardia, A. & Wander, S. A. ESR1 mutation as an emerging clinical biomarker in metastatic hormone receptor-positive breast cancer. Breast Cancer Res. 23, 85 (2021).","journal-title":"Breast Cancer Res."},{"key":"67087_CR36","doi-asserted-by":"publisher","first-page":"5592","DOI":"10.1200\/JCO.2024.42.16_suppl.5592","volume":"42","author":"PA Konstantinopoulos","year":"2024","unstructured":"Konstantinopoulos, P. A. et al. Serial circulating tumor DNA (ctDNA) sequencing to monitor response and define acquired resistance to letrozole\/abemaciclib in endometrial cancer (EC). J. Clin. Oncol. 42, 5592\u20135592 (2024).","journal-title":"J. Clin. Oncol."},{"key":"67087_CR37","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.5858\/arpa.2016-0450-CP","volume":"141","author":"TA Longacre","year":"2017","unstructured":"Longacre, T. A. et al. Template for reporting results of biomarker testing of specimens from patients with carcinoma of the endometrium. Arch. Pathol. Lab. Med. 141, 1508\u20131512 (2017).","journal-title":"Arch. Pathol. Lab. Med."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-67087-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-67087-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-67087-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T22:18:56Z","timestamp":1768342736000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-67087-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,3]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["67087"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-67087-8","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,3]]},"assertion":[{"value":"12 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"P.A.K. declares consulting and\/or advisory board participation for AstraZeneca, Bayer, GSK, Merck, Pfizer, BMS, Repare, IMV, Artios, Kadmon, Cardiff, Immunogen, EMD Serono, Scorpion, Schrodinger, Nimbus, Mural Oncology, unrelated to this work. R.T.P. reports personal fees for advisory boards from Aadi Bioscience, AstraZeneca, GSK Inc., ImmunoGen Inc., Merck & Co., Roche Pharma, Sutro Biopharma; Tubulis Gmbh; Serves on DSMBs for AstraZeneca, EQRx & Roche Pharma; Institutional research funding (as PI): 858 Therapeutics; Royalties from BMJ Publishing, UptoDate, Elsevier Ltd., Wolters Kluwer Health & Wiley Blackwell.; Payment for educational events: Research to Practice, ExpertConnect, ReachMD, CMEO Outfitters, unrelated to this work. J.F.L. declares consulting and\/or advisory board participation for AbbVie, AstraZeneca, Bristol-Myers Squibb, Clovis Oncology, Daiichi Sankyo, Eisai, Genentech\/Roche, Genmab, GlaxoSmithKline, LoxoLilly, Merck, SystImmune, Regeneron Therapeutics, Revolution Medicine, and Zentalis Pharmaceuticals, unrelated to this work. U.A.M. declares participation in scientific advisory boards: NextCure, Abbvie, Immunogen, Profound Bio, Eisai, the Ovarian Cancer Research Alliance, Tango Therapeutics, Novartis, GSK, Daiichi Sankyo, DayOne Bio, and Whitehawk Therapeutics; UAM also reports participation in a data safety-monitoring board: Mural Oncology, Macrogenics, Daiichi Sankyo, Astrazseneca and Symphogen, all unrelated to this work. E.K.L. declares advisory board participation: Aadi Biosciences, Oncusp Therapeutics, Genmab, all unrelated to this work. N.Z., T.V.L., S.C. (Susana Campos), C.K., A.A.W., R.P., N.H., S.B., S.H., H.S., L.K., M.H., M.P., M.S., P.W., S.C. (Su-Chun Cheng), C.C. and J.H.B. declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"395"}}